Edition:
United Kingdom

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

11.12USD
7:35pm GMT
Change (% chg)

$0.22 (+2.02%)
Prev Close
$10.90
Open
$10.93
Day's High
$11.30
Day's Low
$10.93
Volume
17,210
Avg. Vol
51,377
52-wk High
$39.85
52-wk Low
$9.69

Chart for

About

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $187.24
Shares Outstanding(Mil.): 13.28
Dividend: 10.55
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text :[http://bit.ly/2yGsbJv] Further company coverage:

15 Dec 2017

BRIEF-Merrimack reports Q3 loss per share from continuing operations $0.40

* Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40

08 Nov 2017

BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer

* Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer

30 Oct 2017

BRIEF-Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes

* Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020

13 Oct 2017

BRIEF-Merrimack announces settlement of convertible note litigation

* Merrimack announces settlement of convertible note litigation

10 Oct 2017

BRIEF-Merrimack announces date of one-for-ten reverse stock split

* Merrimack announces date of one-for-ten reverse stock split

31 Aug 2017

Competitors

Earnings vs. Estimates